News
Despite soaring demand for GLP-1s, many eligible patients are unable to access these drugs for weight loss
The Brief
- GLP-1 receptor agonists have surged in popularity across the United States.
- The drugs have moved from specialized type 2 diabetes treatments toward weight management and cardiovascular health uses.
- Many patients who are eligible for GLP-1 weight-loss drugs are unable to access them despite the demand.
Why it matters
It shows a gap between who is clinically eligible for GLP-1 weight-loss drugs and who can actually obtain them, which matters for anyone studying obesity treatment or health policy.
Who’s affected
- clinicians and researchers in obesity and cardiometabolic health
- US patients who may be eligible for GLP-1 weight-loss treatment
- #glp-1
- #obesity
- #weight-loss
- #drug-access
- #health-policy
In just a few short years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged in popularity across the United States, transforming from specialized treatments for type 2 diabetes into revolutionary therapeutics for weight management, cardiovascular health and other…